Modulation of riboflavin biosynthesis and utilization in mycobacteria
Microbiology Spectrum · 06.08.2024 · 12 (8)
DOI: 10.1128/spectrum.03207-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 06.08.2024. Verfasst von Melissa D Chengalroyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Mycobacteriology Research Unit, Institute of Infectious Disease and Molecular Medicine & Department of Pathology, University of Cape Town, …. Hauptthemen laut MEDLINE: Riboflavin, Mycobacterium tuberculosis, Mycobacterium smegmatis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | National Institutes of Health (NIH), HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), National Research Foundation (NRF).
Abstract (Originalsprache)
Riboflavin (vitamin B 2 ) is the precursor of the flavin coenzymes, FAD and FMN, which play a central role in cellular redox metabolism. While humans must obtain riboflavin from dietary sources, certain microbes, including Mycobacterium tuberculosis (Mtb), can biosynthesize riboflavin de novo . Riboflavin precursors have also been implicated in the activation of mucosal-associated invariant T (MAIT) cells which recognize metabolites derived from the riboflavin biosynthesis pathway complexed to the MHC-I-like molecule, MR1. To investigate the biosynthesis and function of riboflavin and its pathway intermediates in mycobacterial metabolism and physiology, we constructed conditional knockdowns (hypomorphs) in riboflavin biosynthesis and utilization genes in Mycobacterium smegmatis (Msm) and Mtb by inducible CRISPR interference. Using this comprehensive panel of hypomorphs, we analyzed the impact of gene silencing on viability, on the transcription of (other) riboflavin pathway genes, on the levels of the pathway proteins, and on riboflavin itself. Our results revealed that (i) despite lacking a canonical transporter, both Msm and Mtb assimilate exogenous riboflavin when supplied at high concentration; (ii) there is functional redundancy in lumazine synthase activity in Msm; (iii) silencing of ribA2 or ribF is profoundly bactericidal in Mtb; and (iv) in Msm, ribA2 silencing results in concomitant knockdown of other pathway genes coupled with RibA2 and riboflavin depletion and is also bactericidal. In addition to their use in genetic validation of potential drug targets for tuberculosis, this collection of hypomorphs provides a useful resource for future studies investigating the role of pathway intermediates in MAIT cell recognition of mycobacteria. IMPORTANCE The pathway for biosynthesis and utilization of riboflavin, precursor of the essential coenzymes, FMN and FAD, is of particular interest in the flavin-rich pathogen, Mycobacterium tuberculosis (Mtb), for two important reasons: (i) the pathway includes potential tuberculosis (TB) drug targets and (ii) intermediates from the riboflavin biosynthesis pathway provide ligands for mucosal-associated invariant T (MAIT) cells, which have been implicated in TB pathogenesis. However, the riboflavin pathway is poorly understood in mycobacteria, which lack canonical mechanisms to transport this vitamin and to regulate flavin coenzyme homeostasis. By conditionally disrupting each step of the pathway and assessing the impact on mycobacterial viability and on the levels of the pathway proteins as well as riboflavin, our work provides genetic validation of the riboflavin pathway as a target for TB drug discovery and offers a resource for further exploring the association between riboflavin biosynthesis, MAIT cell activation, and TB infection and disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Mycobacteriology Research Unit, Institute of Infectious Disease and Molecular Medicine & Department of Pathology, University of Cape Town, Cape Town, South Africa.
- Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
- Wellcome Centre for Infectious Disease Research in Africa, University of Cape Town, Cape Town, South Africa.
- Oregon Health and Science University, Portland, Oregon, USA.
- Portland VA Medical Center, Portland, Oregon, USA.
ORCID-Profile: Melissa D Chengalroyen, Digby F Warner, Karen M Dobos, Valerie Mizrahi
Förderung
- HHS | National Institutes of Health (NIH)
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- National Research Foundation (NRF)
- South African Medical Research Council (SAMRC)
- Department of Science and Innovation, South Africa (DSI)
- Colorado State University (CSU)
- Ernest Oppenheimer Memorial Trust (Oppenheimer Memorial Trust)
- NIAID NIH HHS
Zitieren
APA
Chengalroyen, M. D., Mehaffy, C., Lucas, M., Bauer, N., Raphela, M. L., Oketade, N., Warner, D. F., Lewinsohn, D. A., Lewinsohn, D. M., Dobos, K. M., & Mizrahi, V. (2024). Modulation of riboflavin biosynthesis and utilization in mycobacteria. Microbiology Spectrum, 12(8). https://doi.org/10.1128/spectrum.03207-23
Vancouver
Chengalroyen MD, Mehaffy C, Lucas M, Bauer N, Raphela ML, Oketade N, et al. Modulation of riboflavin biosynthesis and utilization in mycobacteria. Microbiology Spectrum. 2024;12(8). doi:10.1128/spectrum.03207-23
BibTeX
@article{Chengalroyen2024,
author = {Chengalroyen, Melissa D and Mehaffy, Carolina and Lucas, Megan and Bauer, Niel and Raphela, Mabule L and Oketade, Nurudeen and Warner, Digby F and Lewinsohn, Deborah A and Lewinsohn, David M and Dobos, Karen M and Mizrahi, Valerie},
title = {Modulation of riboflavin biosynthesis and utilization in mycobacteria},
journal = {Microbiology Spectrum},
year = {2024},
volume = {12},
number = {8},
doi = {10.1128/spectrum.03207-23}
}
EUVIMED